News

Mineralys Therapeutics

Announces $120 Million Private Placement Financing

FEB 8, 2024

Silence Therapeutics

Announces Oversubscribed $120 Million Private Placement

FEB 5, 2024

Adverum Biotechnologies

Announces $127.5 Million Private Placement Financing

FEB 5, 2024

Astria Therapeutics

Announces Pricing Of $125 Million Underwritten Offering

JAN 30, 2024

CG Oncology

Announces Pricing of Upsized Initial Public Offering

JAN 24, 2024

Edgewise Therapeutics

Announces Pricing of $240 Million Underwritten Offering of Common Stock

JAN 19, 2024

TCGX

TCG Crossover (“TCGX”) Announces Oversubscribed $1B TCGX Fund II

JAN 4, 2024

Gracell Biotechnologies

To be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases

DEC 26, 2023

Bristol Myers Squibb

Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

DEC 26, 2023

Icosavax

Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca

DEC 12, 2023

Carmot Therapeutics

Carmot Therapeutics Enters into Definitive Merger Agreement with Roche

DEC 3, 2023

Vistagen

Vistagen Announces Pricing of $100 Million Underwritten Offering

OCT 2, 2023

Structure Therapeutics

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

SEP 29, 2023

COMPASS Pathways

COMPASS Pathways Announces Up to $285 Million Private Placement Financing

AUG 16, 2023

AN2 Therapeutics

AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

AUG 15, 2023

Taysha Gene Therapies

Taysha Gene Therapies Announces $150 Million Private Placement Financing

AUG 14, 2023

ADARx Pharmaceuticals

ADARx Pharmaceuticals Announces Oversubscribed $200 Million Series C Financing

AUG 9, 2023

Gracell Biotechnologies

Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing

AUG 7, 2023

Versanis

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases

JULY 13, 2023

Savara

Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock

JULY 13, 2023

Upstream Bio

Upstream Bio Announces $200M Series B Financing

JUNE 8, 2023

Alkeus

Alkeus Announces $150 Million Series B Financing

JUNE 5, 2023

Carmot

Carmot Therapeutics Raises $150 Million in Series E

MAY 25, 2023

VectivBio

Ironwood Enters into Definitive Agreement to Acquire VectivBio

MAY 22, 2023

Icosavax

Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock

MAY 22, 2023

Iveric Bio

Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

APRIL 30, 2023

Madrigal

Madrigal Announces Positive Topline Results from the Pivotal Phase 3

DECEMBER 19, 2022

Geron

Geron Announces Positive Top-Line Results from IMerge Phase 3

JANUARY 4, 2023

Abivax

Abivax announces successful oversubscribed EUR 130M cross-over financing

FEBRUARY 22, 2023

Structure Therapeutics

Structure Therapeutics Announces Pricing of Upsized Initial Public Offering

FEBRUARY 2, 2023

VectivBio

VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares

OCTOBER 13, 2022

Immunovant

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

OCTOBER 4, 2022

Allakos

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

SEPTEMBER 19, 2022

Abivax

Abivax announces successful oversubscribed EUR 49.2M cross-over financing

SEPTEMBER 2, 2022

Upstream Bio

Upstream Bio Launches with $200M Series A

JUNE 2, 2022

Plexium

Plexium Announces $102M Financing

FEBRUARY 23, 2022

Eikon Therapeutics

Eikon Therapeutics Announces $517.8 Million Series B Raise

JANUARY 6, 2022

Arbor Biotechnologies

Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing

NOVEMBER 9, 2021

Entrada Therapeutics

Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering

OCTOBER 28, 2021

ShouTi

ShouTi Secures $100 Million Series B Financing

OCTOBER 20, 2021

Obsidian

Obsidian Therapeutics Announces Closing of $115 Million Series B Financing

SEPTEMBER 9, 2021

Artios

Artios Announces $153 Million Series C Financing

JULY 27, 2021

RayzeBio

RayzeBio Secures $108 Million Series C Financing

JUNE 15, 2021

Synthekine

Synthekine Announces $107.5 Million Oversubscribed Series B Financing

JUNE 10, 2021

Affinia Therapeutics

Affinia Therapeutics Closes $110 Million Series B Financing

MAY 3, 2021

TCG X

TCG X Raises Inaugural $824 Million Fund to Advance Disruptive Medicines

APRIL 20, 2021

Entrada Therapeutics

Entrada Therapeutics Announces Closing of $116 Million Series B Financing

MARCH 31, 2021

Aktis Oncology

Aktis Oncology Announces $72 Million Series A Financing to Advance Breakthrough Radiopharmaceuticals

MARCH 18, 2021